載入...
Neutralizing antibodies for the treatment of COVID-19
More clinical trial data are needed to determine whether sera from COVID-19-convalescent patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens can prevent COVID-19 or reduce the severity of the disease in high-risk populations.
Na minha lista:
| 發表在: | Nat Biomed Eng |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7891858/ https://ncbi.nlm.nih.gov/pubmed/33293725 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41551-020-00660-2 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|